Catalysts
ASND Stock Catalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
ASNDAscendis Pharma A/S
Healthcare / Biotechnology
Leader
Strong Relative Position
Latest quote
- Momentum75
- Value66
- Quality71
- Risk resilience72
- Sentiment—
Stock Catalyst Board
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
Upcoming reporting date available for this company.
Momentum 75/100 and sentiment — before the next covered event.
Updated Nov 15, 2026 · Sentiment 16.31%
Earnings History And Surprises
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Earnings Expectations And Results
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | — | $0.89 | $1.24 | +38.7% | $409.4M | $418.76M |
| Aug 13, 2026 | — | $1.71 | $3.29 | +92.4% | $376.75M | $387.48M |
| May 7, 2026 | — | $0.19 | $0.32 | +70.6% | $308.93M | $284.92M |
| Feb 11, 2026 | — | -$0.06 | -$0.64 | -966.7% | $292.26M | $344.84M |
| Nov 12, 2025 | — | -$0.41 | -$1.17 | -185.4% | $302.6M | $250.22M |
| Aug 7, 2025 | — | -$1.42 | -$0.93 | +34.5% | $233.12M | $186.09M |
| May 1, 2025 | — | -$1.56 | -$1.66 | -6.4% | $153.48M | $110.67M |
| Feb 12, 2025 | — | -$1.20 | -$0.68 | +43.3% | $125.42M | $180.09M |
Analyst Forecast And Price Targets
Wall Street consensus, rating distribution, and the current 12-month target range.
Event Read
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Next known earnings or reporting date.
Current analyst expectation for the upcoming report.
Current analyst expectation for the upcoming report.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
News And Sentiment
Recent company coverage, scored where source sentiment is available.
Ascendis Pharma Stock Falls 13% Over Share Repurchase Program Authorization
Ascendis Pharma A/S (ASND) is down 13.07 percent, losing $34.64 to $230.28 on Tuesday. The move comes after the biopharmaceutical company announced that its Board of Directors authorized a share repurchase program of up to $400 million of its ordinary shares.
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s stock rose 5% on August 31 after the company announced that it has entered into binding agreements with Ascendis Pharma A/S (NASDAQ:ASND) to resolve a global patent dispute over Ascendis’s achondroplasia drug Yuviwel. The settlement resolves litigation currently pending in numerous jurisdictions, including a Section 337 investigation by the US International […]
Related Links
ASND Catalysts FAQ
What are the next catalysts for ASND stock?
ASND's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
What upcoming events could move ASND stock?
Upcoming events that could move ASND include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
How could ASND's next earnings report affect the stock?
ASND's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
What could drive ASND stock higher?
ASND could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
What events could hurt ASND stock?
ASND could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.